Scott Jeffers
CTO GenSight Biologics
Scott Jeffers, Ph.D., is Chief Technology Officer at GenSight Biologics, where he leads global CMC strategy for AAV-based gene therapy programs, including the commercial development of LUMEVOQ® for Leber Hereditary Optic Neuropathy. With over 20 years of experience in gene therapy and viral vector development, Dr. Jeffers has held senior roles at uniQure, Selecta Biosciences, and Brammer Bio, contributing to the launch of Hemgenix®, the first FDA-approved gene therapy for hemophilia B.
His scientific background includes doctoral research at Purdue University (three U.S. patents in viral vector design), discovery of the SARS-CoV receptor CD209L at the University of Colorado, and structural virology research at the Institut Pasteur, published in Science and PLOS Pathogens.
Dr. Jeffers also founded CGT Resources Now LLC, advising biopharma companies on manufacturing strategy, comparability, and regulatory readiness. A frequent speaker at global bioprocessing conferences, he is recognized for advancing innovation and reliability in gene therapy manufacturing.
Seminars
- Discussing why COGs, not efficacy, may be the greatest barrier to gene therapy adoption
- Sharing lessons from current commercial products: what the numbers really tell us about cost, pricing, and scalability
- Identifying high-impact levers for cost reduction across upstream, downstream, and release processes
- Bridging innovation and economics: what types of investment and collaboration are needed to enable sustainable manufacturing
